A growing movement to rename polycystic ovary syndrome (PCOS) to polycystic ovary and metabolic syndrome (PMOS) is gaining traction, particularly among Black and Latina women who experience higher prevalence and lower diagnosis rates. Advocates say the name change reflects the disorder’s broader metabolic impacts and could reduce stigma while improving early detection and treatment access for underserved communities.
What’s Behind the Name Change
The shift from PCOS to PMOS is not just semantic. Clinicians and patient advocates argue that the new name better captures the disorder’s full spectrum, which includes insulin resistance, obesity, and increased risks of type 2 diabetes and cardiovascular disease. The term "polycystic ovary and metabolic syndrome" emphasizes these systemic effects, moving beyond the narrow focus on ovarian cysts that dominated earlier understandings of the condition.
For decades, PCOS has been framed primarily as a reproductive issue, leading to delayed diagnoses in women who do not present with infertility or irregular periods. This has disproportionately affected Black and Latina women, who are more likely to experience metabolic symptoms first and often face dismissive attitudes from healthcare providers when seeking care.
Why Women of Color Are Disproportionately Affected
Studies show Black and Latina women with PMOS are diagnosed later than their white counterparts, despite exhibiting more severe metabolic symptoms. A 2022 study in the Journal of Clinical Endocrinology & Metabolism found that Black women with PMOS had higher rates of insulin resistance and obesity but were 30% less likely to receive a timely diagnosis. Latina women faced similar disparities, with cultural and language barriers further complicating access to care.
Dr. Marla Lujan, an endocrinologist at Cornell University, notes that implicit bias plays a role. "Providers often overlook metabolic symptoms in women of color, attributing weight gain or fatigue to lifestyle factors rather than investigating underlying endocrine disorders," she says. The renaming of PMOS could help reframe the conversation, encouraging clinicians to consider metabolic markers earlier in the diagnostic process.
How the Name Change Could Improve Outcomes
Advocacy groups like the PCOS Awareness Association and the Black Women’s Health Imperative have endorsed the PMOS terminology, arguing it could reduce stigma and improve patient provider communication. Many women with the disorder report feeling dismissed when told their symptoms are "just PCOS," a phrase that minimizes the condition’s serious long term health risks.
The name change also aligns with broader efforts to destigmatize metabolic health in communities of color. Public health campaigns are increasingly framing PMOS as a systemic issue rather than an individual failing, which could encourage more women to seek care without fear of judgment. Early intervention is critical, as untreated PMOS increases risks for diabetes, heart disease, and endometrial cancer.
What’s Next for PMOS Awareness
While the name PMOS is gaining traction in clinical and advocacy circles, it has not yet been formally adopted by major medical organizations like the American College of Obstetricians and Gynecologists (ACOG) or the World Health Organization. However, grassroots efforts are pushing for wider recognition. Social media campaigns, led by influencers and patient advocates, are amplifying stories of women of color living with PMOS, helping to normalize conversations about the disorder.
Researchers are also calling for more inclusive studies. Most PMOS research has historically focused on white women, leaving gaps in understanding how the disorder manifests across different racial and ethnic groups. New initiatives aim to diversify clinical trials and improve diagnostic criteria to better reflect the experiences of Black and Latina women.
Patient Guidance: What to Do If You Suspect PMOS
Women who experience symptoms like irregular periods, unexplained weight gain, excessive hair growth, or persistent fatigue should seek evaluation from a healthcare provider familiar with PMOS. Key tests include blood work to assess hormone and insulin levels, as well as ultrasounds to check for ovarian cysts. Advocates recommend bringing a list of symptoms to appointments and requesting referrals to endocrinologists if initial evaluations are inconclusive.
For those diagnosed with PMOS, lifestyle changes such as a balanced diet, regular exercise, and stress management can help manage symptoms. Medications like metformin or hormonal birth control may also be prescribed, depending on individual needs. Support groups, both online and in person, can provide valuable resources and community for women navigating the disorder.
Key Takeaways
- The renaming of PCOS to PMOS reflects the disorder’s broader metabolic impacts, potentially improving diagnosis rates for Black and Latina women who face higher prevalence and lower detection.
- Black and Latina women with PMOS are diagnosed later and experience more severe metabolic symptoms, often due to implicit bias and systemic barriers in healthcare.
- Advocacy efforts and public health campaigns are pushing for greater awareness, but formal adoption of the PMOS terminology by major medical organizations is still pending.
Frequently Asked Questions
What is the difference between PCOS and PMOS?
PMOS (polycystic ovary and metabolic syndrome) expands the definition of PCOS to include metabolic symptoms like insulin resistance and obesity, which are often overlooked in traditional PCOS diagnoses.
Why are Black and Latina women more affected by PMOS?
These groups face higher rates of metabolic symptoms but encounter delays in diagnosis due to implicit bias, cultural barriers, and a historical focus on PCOS as a reproductive issue rather than a systemic disorder.
What should I do if I think I have PMOS?
Consult a healthcare provider for blood tests and ultrasounds to assess hormone and insulin levels. If symptoms persist, seek a referral to an endocrinologist for specialized care.
Published by O. Ayodeji John | Review by MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT